|
Designated Public Office Holders who participated in the communication:
|
Miro Froehlich,
Director of Policy
Privy Council Office (PCO)
|
| |
List of Details
|
Subject matter
|
Detail
|
|
Health,
Intellectual Property
|
Policies and frameworks to accelerate access to innovative medicines
post-Health Canada approval, including efforts to reduce time-to- reimbursement and streamline federal/provincial listing processes
Policy measures to ensure security of drug supply in Canada and
preserve Canada's attractiveness for biopharmaceutical launches,
including in response to foreign pricing regulations
|
|
| |
|
Responsible Officer who filed this communication report:
|
Viktoria Friedrich
|
| |
|
As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication. The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed.
|
| |
